Absolute lymphocyte count at day 15 (ALC-15) after autologous peripheral blood hematopoietic stem cell transplantation (APHSCT) is an independent prognostic factor for survival in multiple myeloma (MM); however, factors affecting ALC-15 in MM remain unknown. We hypothesized that the dose of infused peripheral blood autograft lymphocytes (autograft absolute lymphocyte count: A-ALC) impacts ALC-15 recovery. Between 1989 and 2001, 267 consecutive MM patients underwent APHSCT. We set out to determine the correlation between A-ALC and ALC-15 and the utility of A-ALC as a marker for ALC-15 recovery. A-ALC was found to be both a strong predictor for area under curve (AUC ¼ 0.93; P ¼ 0.0001) and strongly correlated with (r s ¼ 0.83; P ¼ 0.0001) ALC-15 recovery. Higher infused A-ALC was significantly correlated with an ALC-15X500/ll. In addition, median post-transplant overall survival (OS) and time to progression (TTP) were longer in patients who received an A-ALCX0.5 Â 10 9 lymphocytes/kg versus A-ALC o0.5 Â 10 9 lymphocytes/kg (58 vs 30 months, P ¼ 0.00022; 22 vs 15 months, Po0.00012, respectively). Multivariate analysis demonstrated A-ALC as an independent prognostic indicator for OS and TTP. These results indicate that an infused dose of autograft lymphocytes significantly impacts clinical outcome post-APHSCT in MM.
Introduction
Absolute lymphocyte count recovery at day 15 (ALC-15) after autologous peripheral blood hematopoietic stem cell transplantation (APHSCT) has been reported as a powerful, independent prognostic indicator of clinical outcomes for patients with acute myelogenous leukemia, 1 4 (Herr et al. Blood 2002; 100: abstract #5496). We have recently reported that the dose of infused lymphocytes of the peripheral blood autograft (autograft absolute lymphocyte count: A-ALC) correlates with ALC-15 and clinical outcome in non-Hodgkin's lymphoma post-APHSCT. 6 In this study, we evaluated the hypothesis that ALC-15 is also directly dependent on A-ALC in patients with MM.
Materials and methods

Patient population
Between 1989 and 2001, a total of 385 autologous stem cell transplants have been performed at the Mayo Clinic for patients with plasma cell proliferative disorders. A total of 267 of the 385 (69%) consecutive patients were eligible for the study. In all, 11 patients had two transplants, and only data from the first transplant were included in the study. The second transplant was performed after patients relapsed from the first autologous stem cell transplantation. A total of 10 patients had a second autologous stem cell transplantation, and one patient had a nonmyeloablative stem cell transplantation. Patients who underwent autologous transplantation for POEMS syndrome (one patient), amyloidosis (92 patients), or concomitant diagnosis of amyloidosis and MM (four patients) were excluded from the study (ALC-15 has not been reported to be an independent prognostic factor in these specific groups of plasma proliferative disorders). Only patients who received APHSCT for MM were included in the study. Patients who received bone marrow harvest (21 patients) were also excluded. Data for this retrospective study were prospectively collected over time and entered into a computerized database. Response to therapy, relapse, and survival data were updated continuously. No patients were lost to follow-up. All patients gave written, informed consent allowing the use of their medical records for medical research. Approval of the study was obtained from the Mayo Clinic Institutional Review Board and was in accordance with US federal regulations and the Declaration of Helsinki.
End points
The primary end point of the study was to determine the agreement as well as the correlation between A-ALC and ALC-15. Secondary end points included the impact of A-ALC on overall survival (OS) and time to progression (TTP) from the time of transplant. ALC-15 was obtained from the standard complete blood cell count, and the infused A-ALC for each apheresed unit collection was calculated as follows: A-ALC ¼ (% collection lymphocytes) Â (absolute WBC)/kg.
Prognostic factors
Prognostic factors for posttransplant OS and TTP evaluated in this study included age at transplant, beta-2 microglobulin (b2M), bone marrow plasma cells (BMPC), circulating plasma cells, C-reactive protein (CRP), cytogenetics, disease status at transplantation, lactate dehydrogenase (LDH), number of pretransplant chemotherapy regimens, and plasma cell labeling index (PCLI). In addition, the principal factors being tested in relation to these clinical outcomes were ALC-15 recovery (ALC-15X500/ml versus ALC-15o500/ml) and infused A-ALC (X0.5 Â 10 9 lymphocytes/kg vs A-ALCo0.5 Â 10 9 lymphocytes/kg). Beyond evaluating potential prognostic factors for OS and TTP, the factors above were also independently assessed in association with ALC-15 recovery as well as A-ALC. Additional factors evaluated in association with ALC-15 recovery included CD34 cell dose, conditioning regimens, posttransplant cytokines (G-CSF vs GM-CSF), premobilization ALC, and gender. Further factors evaluated in association with A-ALC included premobilization ALC, mobilization regimen type, gender, CD34 cell dose, and peripheral count of absolute lymphocyte count (PC-ALC) at the time of apheresis collection.
Peripheral blood stem cell (lymphocyte autograft) collection
Eight patients with MM were mobilized with granulocytemacrophage colony-stimulating factor (GM-CSF) (5 mg/kg) daily by subcutaneous injection. The remaining 259 MM patients received cyclophosphamide (3 gm/m 2 ) total dose divided for 2 days followed by GM-CSF (500 mcg) or G-CSF (10 mg/kg) daily for 10-15 consecutive days by subcutaneous injection. Apheresis sessions were performed in 199 patients with the Fenwall CS3000-plus, 33 patients with the Fenwall Amicus, and 35 patients with the Cobra Spectra blood-cell collectors. In all, 10-12 l of blood was processed daily, at flow rates of 50-60 ml/min using a Hickman catheter or antecubital veins. Patients underwent daily apheresis sessions until a target of 2.0 Â 10 6 CD34 cells/kg or greater was achieved. Prestem cell mobilization ALC was obtained from a complete blood cell count prior to stem cell mobilization. 
Conditioning regimens
Statistical analysis
OS and TTP were analyzed using the approach of Kaplan and Meier. 7 Differences between survival curves were tested for statistical significance using the two-tailed log-rank test. The Cox proportional hazards model 8 was used to evaluate A-ALC as a prognostic factor for post-transplant OS and TTP times as well as to assess and adjust for other known prognostic factors. Risk ratios reported are for risks associated with patients having high (X0.5 Â 10 9 lymphocytes/kg) vs low (o0.5 Â 10 9 lymphocytes/ kg) A-ALC values. Other prognostic factors tested included age at transplant (50 years or older), b2M (42.7 mg/dl), BMPC (440%), circulating plasma cells (X1%), CRP (40.8 mg/dl), cytogenetics (normal vs aneuploid), disease status at transplantation (plateau/response vs relapsed/refractory), LDH (elevated for age/sex), number of pretransplant chemotherapy regimens, and PCLI (X1%).
In addition to the evaluation of A-ALC and its prognostic significance for OS and TTP, its utility as a marker for ALC-15 recovery (X500 cells/ml) was also assessed (Figure 1 ). This cutoff and definition of ALC-15 recovery after APHSCT was used based on our previous publications. [1] [2] [3] [4] The choice of optimal cutoff of infused A-ALC was based on its utility as a marker for ALC-15 recovery using box plot, ROC curves, and area under the curve (AUC) analyses as well as its prognostic value for post-transplant OS. Prediction of ALC-15 recovery was explored further in logistic regression models, univariately assessing continuous and dichotomized values of A-ALC as well as the other potential prognostic factors described above. w 2 -tests were used to determine relationships between categorical variables; twosample t-tests (and Wilcoxon rank-sum tests as appropriate) and Spearman correlation coefficients were used to evaluate 
Figure 1
Box plot of Infused A-ALC in patients with an ALC-15 recovery X500 cells/ml at day 15 and patients with an A-ALC recovery o500 cells/ml at day 15 after APHSCT. The horizontal line within each box represents the median, and the lower and upper borders of each box represent the 25th and the 75th percentiles, respectively. Outliers (values that exceed these boundaries) are depicted as single points. The median A-ALC was significantly higher in those patients with an ALC-15X500 cells/ml vs an ALC-15o500 cells/ml after APHSCT (0.64 Â 10 9 vs 0.2 Â 10 9 lymphocytes/kg, respectively; P ¼ 0.0001).
associations for continuous variables. All P-values represented were two-sided, and statistical significance was declared at Po0.05.
Results
Patient characteristics
The median age at the time of transplant for this cohort of 267 patients was 57 years (range: 30-75). Distributions of additional baseline characteristics for these patients are presented in Table 1 and are summarized based on whether patients received o0.5 Â 10 9 lymphocytes/kg vs X0.5 Â 10 9 lymphocytes/kg. In the plateau/response group, 12 patients were in CR prior to stem cell transplantation, and the rest were in PR. The only statistical differences observed between the groups were the ALC-15, stem cell mobilization regimens, and conditioning regimens. None of the patients received purged or CD34-selected stem cells.
The median follow-up on living patients in this cohort was 25 months (range: 2-107). At the time of these analyses, 111 patients (42%) had died and 197 (74%) had progressed after transplant. The day 100 transplant-related mortality for the cohort group was only 4% (10/267). Only two of 10 patients received an autograft with A-ALCX0.5 Â 10 9 lymphocytes/kg; one patient died of pneumonia and the other of sepsis. Eight patients received A-ALCX0.5 Â 10 9 lymphocytes/kg; two patients died of sepsis, two patients of respiratory failure, one patient of intracranial hemorrhage, one patient of disseminated varicella, and one patient committed suicide. Although the improved early mortality rate may be associated with ALC recovery, the data are insufficient to make any statistically relevant conclusions. None of the patients developed clinically evident autologous graft-vs-host disease.
Role of infused autograft lymphocytes on ALC-15
In an attempt to identify factors that influence early post-APHSCT ALC-15 recovery, we assessed the utility of infused A-ALC as a marker for this relevant clinical outcome. Box plots showed some overlap in the infused A-ALC dose between ALC-15X500 cells/ml and ALC o500cells/ml; however, there was still a substantial separation between these two groups ( Figure 2 ). ROC and sensitivity/specificity curves and AUC analyses showed that A-ALC was a significant marker for ALC-15 recovery (AUC ¼ 0.93, Po0.0001; Figures 2 and 3) . Based on these results as well as evaluating various A-ALC cutoffs as prognostic factors for OS, an A-ALC cutoff of 0.5 Â 10 9 lymphocytes/kg was considered optimal. Therefore, this cutoff is evaluated for A-ALC in all subsequent analyses in this study.
With regard to the association between ALC-15 recovery and the A-ALC cutoff, these dichotomized variables were found to be significantly correlated with each other (Po0.0001) as were their continuous counterparts (r s ¼ 0.83, Po0.0001; Figure 4) . Logistic regression models for predicting ALC-15 recovery further indicate that A-ALC is significantly correlated with this clinical outcome (Po0.0001). Other significant factors for ALC-15 recovery in the univariate setting included blood-cell collectors (P ¼ 0.0001), elevated LDH (P ¼ 0.048), and conditioning regimen (P ¼ 0.0002). When these factors were accounted for in addition to A-ALC in a multivariable logistic regression model, A-ALC was the only remaining significant correlate for ALC-15 (Po0.0001). An A-ALCX0.5 Â 10 9 lymphocytes/kg was associated with an adjusted odds ratio for ALC- 15 of 60 (95% CI, 27.1-150.9). We did not identify any correlation between A-ALC and the number of prior chemotherapy regimens (P ¼ 0.20), the number of CD34 cells collected (P ¼ 0.67), and the disease status at transplantation (P ¼ 0.29).
Post-transplant survival and infused A-ALC
The median post-transplant OS (Figure 5a ) and TTP (Figure 5b ) times were significantly better for patients infused with A-ALCX0.5 Â 10 9 lymphocytes/kg compared with patients infused with A-ALCo0.5 Â 10 9 lymphocytes/kg (58 vs 30 months, P ¼ 0.00022; 22 vs 15 months, P ¼ 0.00012, respectively). By day 100 post-APHSCT, 48 patients achieved CR, 41 patients PR, and one patient showed progression of disease in A-ALCX0.5 Â 10 9 lymphocytes/kg group. In A-ALCo0. lymphocytes/kg. The median overall survival was 58 months in the group of patients with an A-ALCX0.5 Â 10 9 lymphocytes/kg and 30 months in the group of patients with an A-ALCo0.5 Â 10 9 lymphocytes/kg. The OS rates at four years were 52 and 30%, respectively (P ¼ 0.0002). (b) TTP of patients infused with an A-ALCX0.5 Â 10 9 lymphocytes/kg vs patients with an infused A-ALCo0.5 Â 10 9 lymphocytes/kg. The median progression-free survival was 22 months in the group of patients with an A-ALCX0.5 Â 10 9 lymphocytes/kg and 15 months in the group of patients with an A-ALCo0.5 Â 10 9 lymphocytes/kg. The progression-free survival rates at four years were 24 and 12%, respectively (P ¼ 0.0001).
Infused lymphocyte dose and clinical outcome after APBHSCT LF Porrata et al (P ¼ 0.0001). To assess any difference in the relapse rate between the A-ALCX0.5 Â 10 9 lymphocytes/kg group vs the A-ALCo0.5 Â 10 9 lymphocytes/kg group, we compared the relapse rates at 1 year post-APHSCT. Of the 267 patients, 234 patients had follow-up for a year or more. Of the 85 patients in the A-ALCX0.5 Â 10 9 lymphocytes/kg group, only 18 patients relapsed at 1 year post-APHSCT for a relapse rate of 21%. Of the 149 patients in the A-ALCo0.5 Â 10 9 lymphocytes/kg group, 58 patients relapsed at 1 year post-APHSCT for a relapse rate of 39%. The difference of relapse rates between the groups was statistically significant (P ¼ 0.0058). Other significant factors in univariate analyses for OS included b2M, CRP, circulating plasma cells, PCLI, BMPC, disease status, the number of prior chemotherapy regimens, and abnormal cytogenetics (see Table 2 ). However, when all of these factors were accounted for in a multivariable model, only A-ALC, CRP, PCLI, and abnormal cytogenetics remained significant factors (Table 3) . Similarly, univariate analyses showed that A-ALC was a significant factor for TTP, in addition to circulating plasma cells, PCLI, BMPC, abnormal cytogenetics, disease status, and the number of prior chemotherapy regimens. Multivariable analyses showed that only A-ALC and PCLI remained significant factors for TTP when all variables were accounted for in the model. Given the strong correlation and agreement between A-ALC and ALC-15 recovery, only A-ALC was included in the multivariable model. When only ALC-15 recovery was included, similar results were seen as for A-ALC.
As disease status at transplantation was identified as an important prognostic factor, we studied the outcome of patients with relapse/refractory disease status prior to transplantation. Of the 156 patients with relapse/refractory disease status at transplantation, 56 patients received A-ALCX0.5 Â 10 9 lymphocytes/kg and 100 patients received A-ALCo0.5 Â 10 9 lymphocytes/kg. In all, 29 patients are alive and 27 patients are dead in the A-ALCX0.5 Â 10 9 lymphocytes/kg group, and in the A-ALCo0.5 Â 10 9 lymphocytes/kg group, 48 patients are alive and 52 patients are dead. The day 100 response for patients with A-ALCX0.5 Â 10 9 lymphocytes/kg was that 31 patients achieved CR and 25 patients PR. In the AALCo0.5 Â 10 9 lymphocytes/kg group, 22 patients achieved CR, 73 patients PR, three patients showed progression, and two patients stable disease. The difference between CR rates at day 100 post-APHSCT was statistically significant (A-ALCX0.5 Â 10 9 lymphocytes/kg was 55% vs A-ALC o0.5 Â 10 9 lymphocytes/kg was 22%; P ¼ 0.0001). The median OS and TTP times were significantly better for patients infused with A-ALCX0.5 Â 10 9 lymphocytes/kg compared with patients infused with A-ALC o0.5 Â 10 9 lymphocytes/kg (45.8 vs 24.5 months, P ¼ 0.0041; 17.1 vs 11.1 months, P ¼ 0.002, respectively). A-ALC was a significant factor for OS in addition to cytogenetics, CRP, PCLI and for TTP in addition to cytogenetics and BMPC by univariate analyses. In multivariate analyses, A-ALC was an independent predictor for OS (RR ¼ 0.66, 0.52-0.85 95% CI, P ¼ 0.0008) and TTP (RR ¼ 0.71, 0.58-0.86 95% CI, Infused lymphocyte dose and clinical outcome after APBHSCT LF Porrata et al P ¼ 0.0004) when compared to the significant predictors identified in the univariate analysis.
Autograft peripheral blood absolute lymphocyte count
The identification of A-ALC as an independent prognostic factor for survival, its strong correlation with ALC-15, and its significance as a marker for ALC-15 recovery led us to investigate the factors that may influence A-ALC collection. Specifically, we assessed the association of various potential factors on the ability to collect X0.5 Â 10 9 lymphocytes/kg. In univariate analyses, only PC-ALC (P ¼ 0.0001) and mobilization regimen type (P ¼ 0.01) were significantly associated with A-ALC collection X0.5 Â 10 9 lymphocytes/kg. In a multivariable model, PC-ALC was the only remaining significant factor for A-ALC collection X0.5 Â 10 9 lymphocytes/kg (Po0.0001). The corresponding adjusted odds ratio was 34.7 (95% CI: 16.7-78.2). ROC and associated AUC analyses showed that PC-ALC was a significant marker for A-ALC (AUC ¼ 0.85, P ¼ 0.0001). Based on these results, we evaluated different PC-ALC cutoff values to predict a higher A-ALC collection. We identified a PC-ALCX0.5 Â 10 9 /l as the threshold value predicting an A-ALCX0.5 Â 10 9 lymphocytes/kg collection ( Figure 6 ).
Discussion
MM patients achieving an ALC-15X500 cells/ml after APHSCT have a superior survival compared with patients achieving an ALC-15o500 cells/ml. 4 We have recently reported in nonHodgkin's lymphoma patients that A-ALC directly impacts ALC-15 recovery and survival post-APHSCT. 6 Therefore, we set out to identify if A-ALC influences ALC-15 and clinical outcomes of MM patients treated with APHSCT.
The stratification of our cohort group based on A-ALCX0.5 Â 10 9 lymphocytes/kg was balanced for all patients' characteristics and prognostic factors except for ALC-15, conditioning regimens, and stem cell mobilization regimens. The reason for the difference between both groups for the conditioning regimens and stem cell mobilization regimens is based on our clinical practice. Chemotherapy plus growth factor has been our standard stem cell mobilization regimen compared with growth factor alone. Melphalan plus TBI was our standard conditioning regimen until 200 mg/m 2 of melphalan was proven to be less toxic and as effective when compared with melphalan and TBI. 9 No independent correlation was identified between ALC-15 and patients' baseline characteristics and prognostic factors except for A-ALC in our cohort of MM patients. Herein, we present data supporting the observation that ALC-15 post-APHSCT is directly dependent on the dose of infused lymphocytes (A-ALC) with direct influence on clinical end points.
Our study shows a strong positive correlation between infused A-ALC and ALC-15 after AHPSCT. In addition, the study analyzed the number of infused A-ALC stratified by ALC-15X500 cells/ml vs ALC-15o500 cells/ml after APHSCT. We found that the number of infused A-ALC was a significant marker for patients achieving an ALC-15X500 cells/ml (Po0.0001). Our data corroborate previous publications describing the impact of the re-infused graft lymphocytes with lymphocyte recovery post-transplantation. In the autologous setting, patients receiving auto-peripheral blood progenitor cells (PBPC) resulted in faster total lymphocyte counts and T cell subsets recovery compared to patients receiving auto-bone marrow harvest (BMT), which was explained by the higher number of lymphocytes within the blood stem cell product. [10] [11] [12] Several studies have demonstrated a faster lymphocyte recovery for patients receiving autologous unmanipulated PBPC compared with patients receiving CD34 þ -selected autologous peripheral blood stem cells. [13] [14] [15] The studies of autologous unmanipulated PBPC vs CD34 þ -selected stem cell transplantations have mainly addressed the potential for life-threatening opportunistic infections based on the immune reconstitution from these two sources of apheresis collection. In MM, the role of purging on survival after APHSCT by minimizing the re-infusion of tumor cells from the stem cell product has been studied by comparing CD34-selected stem cells vs unmanipulated PBPCs. No difference in overall or progression-free survival has been reported between CD34-selected vs unmanipulated PBPCs transplants in MM. [16] [17] [18] However, no consideration was given to the impact of immune reconstitution on the underlying malignancy. To our knowledge, our current study demonstrates the first evidence that the infused A-ALC have a direct impact on survival after APHSCT in MM patients. We identified that MM patients receiving higher numbers of infused A-ALC (X0.50 Â 10 9 lymphocytes/kg) experienced higher response rates and lower relapse rates, resulting in improved survival after APHSCT. A-ALC was identified as an independent prognostic factor for overall survival and progression-free survival in MM patients undergoing APHSCT. This supports our contention that the infused A-ALC plays an important role in the clinical outcomes of MM patients undergoing APHSCT. No correlation was identified between A-ALC and patients' baseline characteristics and prognostic factors except for PC-ALC. As A-ALC depends on PC-ALC, we found no association between patients' baseline characteristics and prognostic factors and PC-ALC (data not shown). However, there was statistical difference in the median number of PC-ALC at the time of collection of patients that were mobilized with growth factor only (GM-CSF) vs patients mobilized with chemotherapy (CTX) plus growth factor (0.77 Â 10 9 /l vs 0.28 Â 10 9 /l, respectively, Po0.0007). These data suggest that the stem cell mobilization regimen might be an important factor of A-ALC collection by affecting PC-ALC. Studies comparing stem cell mobilization by growth factor alone vs chemotherapy plus growth factor in MM have mainly addressed the issue of hematopoietic recovery post-APHSCT. This number was not sufficient to allow relevant statistical comparisons. A study comparing balanced numbers of MM patients mobilized with growth factor alone vs chemotherapy plus growth factor would help to directly evaluate the role of stem cell mobilization regimens in lymphocyte collection and clinical outcome post-APHSCT in MM.
The specific lymphocyte subsets in the infused A-ALC and ALC-15 after APHSCT associated with survival are not known due to the retrospective nature of the study. Few studies have reported that infusion of autologous lymphocytes in addition to stem cells result in rapid reconstitution of CD4 and CD8 T cells but failed to demonstrate any association with survival. 20 T cells and natural killer (NK) cells have been reported to be the main lymphocyte subsets collected during stem cell mobilization. 21 Studies of immuno-reconstitution after APHSCT have shown delayed recovery of T and B cells following stem cell transplantation. 22, 23 However, normal NK cell number and function recovery has been documented as early as 2 weeks after APHSCT. 24 We have recently reported that the infused autograft peripheral blood NK cells directly correlate with ALC-15. 25 In addition, preliminary data suggest that patients with normal absolute numbers of NK cells have a superior survival compared to patients with low absolute numbers of NK cells by ALC-15 (Porrata et al. Blood 2003; 102: Abstract #3680). Antimyeloma activity has been reported by NK cells. [26] [27] [28] This argues in favor of the clinical significance of early NK cell engraftment as a manifestation of early reconstitution of antitumor immunosurveillance and its direct impact on ALC-15 and survival post-APHSCT.
In summary, our study demonstrates a strong positive correlation between the infused A-ALC and ALC-15 post-APHSCT directly influencing survival in MM after APHSCT. This is the first study showing that the infused A-ALC is critically important for survival in MM patients after APHSCT. The correlation of A-ALC with ALC-15 and survival after APHSCT suggests that the stem cell mobilization and collection should not be viewed only as a means to achieve hematopoietic engraftment, but also as a means to achieving immunologic engraftment with direct consequences to clinical outcome. We hope that these data will support further investigations directed at maximizing post-APHSCT immunologic recovery.
